<p>Legend Biotech（纳斯达克：LEGN - 获取免费报告）的股票在周三的一份研究报告中被 HC Wainwright 的股票研究员重申为&#34;买入&#34;评级，据 Benzinga 报道。他们目前对该股票设定了 73.00 美元的目标价。HC Wainwright 的目标价表明，相较于公司当前股价，可能有 62.55% 的潜在上涨空间。</p>
<p>获取 <strong>Legend Biotech</strong> 的警报：</p>
<ul>
<li>CPI 数据激发生物科技股上涨</li>
</ul>
<p>其他分析师也发布了有关该股票的报告。Scotiabank 将 Legend Biotech 的目标价从 70.00 美元上调至 76.00 美元，并在 8 月 12 日星期一的研究报告中给予公司&#34;行业表现优异&#34;的评级。BMO Capital Markets 重申了&#34;买入&#34;评级，并在 7 月 3 日星期三的研究报告中对 Legend Biotech 的股票设定了 90.00 美元的目标价。加拿大皇家银行在 9 月 27 日星期五的研究报告中重申了&#34;买入&#34;评级，并对 Legend Biotech 的股票设定了 86.00 美元的目标价。TD Cowen 在 7 月 15 日星期一的研究报告中将 Legend Biotech 的目标价从 71.00 美元下调至 67.00 美元，并对该股票给予&#34;买入&#34;评级。最后，Redburn Atlantic 在 10 月 8 日星期二的研究报告中开始对 Legend Biotech 的股票进行覆盖。他们给予该股票&#34;买入&#34;评级，并设定了 86.00 美元的目标价。根据 MarketBeat 的数据，共有十四位股票研究分析师对该股票给予了买入评级。Legend Biotech 的共识评级为&#34;买入&#34;，平均目标价为 82.08 美元。</p>
<p><strong>查看我们对 LEGN 的最新股票分析</strong></p>
<h2>Legend Biotech 股票下跌 9.6%</h2>
<ul>
<li>为什么 Legend Biotech 股票有了最佳月份</li>
</ul>
<p>Legend Biotech 股票周三开盘价为 44.91 美元。Legend Biotech 的 12 个月最低价为 38.60 美元，最高价为 70.78 美元。该公司的流动比率为 4.84，速动比率为 4.78，负债权益比为 0.25。该股票的市值为 81.9 亿美元，市盈率为-34.55，贝塔系数为 0.10。公司的 50 天移动平均价为 52.19 美元，200 天移动平均价为 49.54 美元。</p>
<p>Legend Biotech（纳斯达克：LEGN - 获取免费报告）于 8 月 9 日星期五发布了季度财报。公司报告的每股收益为（0.05）美元，超过了每股（0.54）美元的共识预期 0.49 美元。该季度公司营收为 1.865 亿美元，超过分析师预期的 1.2525 亿美元。Legend Biotech 的净利润率为-62.50%，净资产收益率为-23.20%。公司季度营收同比增长了 154.4%。在去年同期，公司每股收益为（0.27）美元。研究分析师平均预计，Legend Biotech 在本财年将实现-1.51 美元的每股收益。</p>
<h2>对 Legend Biotech 的对冲基金看法</h2>
<p>最近，许多对冲基金对 LEGN 的持股进行了调整。Blue Trust Inc.在第二季度将其对 Legend Biotech 的持股增加了 10,075.0%。Blue Trust Inc.现在拥有公司股票 814 股，价值 36,000 美元，在上一季度购买了额外的 806 股。美国国际集团在第一季度将其对 Legend Biotech 的持股增加了 50.0%。美国国际集团现在拥有公司股票 900 股，价值 50,000 美元，在该期间额外增持了 300 股。AM Squared Ltd 在第二季度购入了一笔新的 Legend Biotech 持股，价值 71,000 美元。加州教师退休金基金在第一季度将其对 Legend Biotech 的持股增加了 196.3%。加州教师退休金基金现在拥有公司股票 3,345 股，价值 188,000 美元，在该期间额外增持了 2,216 股。最后，法国巴黎银行在第一季度购入了一笔新的 Legend Biotech 持股，价值 199,000 美元。机构投资者和对冲基金共拥有公司股份的 70.89%。</p>
<h2>Legend Biotech 公司简介（获取免费报告）</h2>
<p>Legend Biotech Corporation 是一家临床阶段生物制药公司，通过其子公司在美国、中国和国际市场从事新型细胞疗法在肿瘤学和其他适应症中的发现、开发、制造和商业化。其主要产品候选药物 LCAR-B38M 是一种用于多发性骨髓瘤（MM）治疗的嵌合抗原受体。</p>
<h2>另请参阅</h2>
<ul>
<li>我们喜欢的五只股票胜过 Legend Biotech</li>
<li>股市行业：有多少种？</li>
<li>Salesforce：您看到最新的价格目标升级了吗？</li>
<li>什么是盈利报告？</li>
<li>Bright Minds Biosciences 股票涨幅近 1500%</li>
<li>房地产投资信托股票 - 添加到您的投资组合中的最佳房地产投资信托股票</li>
<li>查尔斯·施瓦布：稳定的表现，但还有更多要来吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEVHTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEVHTg"/></p>
<p><em>这则即时新闻警报是由 Narrative Science 技术和 MarketBeat 的财务数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 您准备好迎接 11 月 5 日了吗（来自 Weiss Ratings）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05OTg4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05OTg4"/></p>
<h2>您现在是否应该投资 1000 美元购买 Legend Biotech 股票？</h2>
<p>在考虑 Legend Biotech 之前，您可能希望听听这个。</p>
<p>MarketBeat 每天跟踪华尔街评级最高且表现最佳的研究分析师以及他们向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 Legend Biotech 并不在这份名单上。</p>
<p>尽管传奇生物目前在分析师中拥有&#34;买入&#34;评级，但顶级分析师认为以下五只股票更值得购买。</p>
<p>查看这五只股票</p>

传奇生物

<p>HC Wainwright 重申对传奇生物（NASDAQ: LEGN）的 “买入” 评级，并设定目标价格，暗示潜在上涨幅度为 62.55%。其他分析师也对该股票给予了积极评价，共识评级为 “买入”，平均目标价格为 0.08 美元。该公司报告了年度收入增长 154.4%，尽管净利润率为负。机构投资者持有该股的 70.89%，表明他们对这家专注于开发肿瘤新型细胞疗法的公司表现出强烈兴趣</p>

<p>Legend Biotech (NASDAQ:LEGN - Get Free Report)'s stock had its &#34;buy&#34; rating reiterated by equities researchers at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They currently have a $73.00 target price on the stock. HC Wainwright's target price would suggest a potential upside of 62.55% from the company's current price.</p>
<div class="lb-trans"><p>Legend Biotech（纳斯达克：LEGN - 获取免费报告）的股票在周三的一份研究报告中被 HC Wainwright 的股票研究员重申为&#34;买入&#34;评级，据 Benzinga 报道。他们目前对该股票设定了 73.00 美元的目标价。HC Wainwright 的目标价表明，相较于公司当前股价，可能有 62.55% 的潜在上涨空间。</p>
</div><p>Get <strong>Legend Biotech</strong> alerts:</p>
<ul>
<li>CPI Data Sparks Rally in Biotech Stocks</li>
</ul>
<div class="lb-trans"><p>获取 <strong>Legend Biotech</strong> 的警报：</p>
<ul>
<li>CPI 数据激发生物科技股上涨</li>
</ul>
</div><p>Other analysts have also issued reports about the stock. Scotiabank increased their price target on shares of Legend Biotech from $70.00 to $76.00 and gave the company a &#34;sector outperform&#34; rating in a research report on Monday, August 12th. BMO Capital Markets reiterated an &#34;outperform&#34; rating and issued a $90.00 price target on shares of Legend Biotech in a research report on Wednesday, July 3rd. Royal Bank of Canada reiterated an &#34;outperform&#34; rating and issued a $86.00 price target on shares of Legend Biotech in a research report on Friday, September 27th. TD Cowen decreased their target price on shares of Legend Biotech from $71.00 to $67.00 and set a &#34;buy&#34; rating on the stock in a research report on Monday, July 15th. Finally, Redburn Atlantic began coverage on shares of Legend Biotech in a research report on Tuesday, October 8th. They set a &#34;buy&#34; rating and a $86.00 target price on the stock. Fourteen equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Legend Biotech has a consensus rating of &#34;Buy&#34; and an average price target of $82.08.</p>
<div class="lb-trans"><p>其他分析师也发布了有关该股票的报告。Scotiabank 将 Legend Biotech 的目标价从 70.00 美元上调至 76.00 美元，并在 8 月 12 日星期一的研究报告中给予公司&#34;行业表现优异&#34;的评级。BMO Capital Markets 重申了&#34;买入&#34;评级，并在 7 月 3 日星期三的研究报告中对 Legend Biotech 的股票设定了 90.00 美元的目标价。加拿大皇家银行在 9 月 27 日星期五的研究报告中重申了&#34;买入&#34;评级，并对 Legend Biotech 的股票设定了 86.00 美元的目标价。TD Cowen 在 7 月 15 日星期一的研究报告中将 Legend Biotech 的目标价从 71.00 美元下调至 67.00 美元，并对该股票给予&#34;买入&#34;评级。最后，Redburn Atlantic 在 10 月 8 日星期二的研究报告中开始对 Legend Biotech 的股票进行覆盖。他们给予该股票&#34;买入&#34;评级，并设定了 86.00 美元的目标价。根据 MarketBeat 的数据，共有十四位股票研究分析师对该股票给予了买入评级。Legend Biotech 的共识评级为&#34;买入&#34;，平均目标价为 82.08 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on LEGN</strong></p>
<div class="lb-trans"><p><strong>查看我们对 LEGN 的最新股票分析</strong></p>
</div><h2>Legend Biotech Trading Down 9.6 %</h2>
<ul>
<li>Why Legend Biotech Stock Is Having Its Best Month Yet</li>
</ul>
<div class="lb-trans"><h2>Legend Biotech 股票下跌 9.6%</h2>
<ul>
<li>为什么 Legend Biotech 股票有了最佳月份</li>
</ul>
</div><p>Shares of Legend Biotech stock opened at $44.91 on Wednesday. Legend Biotech has a 12-month low of $38.60 and a 12-month high of $70.78. The company has a current ratio of 4.84, a quick ratio of 4.78 and a debt-to-equity ratio of 0.25. The stock has a market cap of $8.19 billion, a PE ratio of -34.55 and a beta of 0.10. The company has a 50-day moving average of $52.19 and a two-hundred day moving average of $49.54.</p>
<div class="lb-trans"><p>Legend Biotech 股票周三开盘价为 44.91 美元。Legend Biotech 的 12 个月最低价为 38.60 美元，最高价为 70.78 美元。该公司的流动比率为 4.84，速动比率为 4.78，负债权益比为 0.25。该股票的市值为 81.9 亿美元，市盈率为-34.55，贝塔系数为 0.10。公司的 50 天移动平均价为 52.19 美元，200 天移动平均价为 49.54 美元。</p>
</div><p>Legend Biotech (NASDAQ:LEGN - Get Free Report) last released its quarterly earnings results on Friday, August 9th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.49. The business had revenue of $186.50 million for the quarter, compared to analyst estimates of $125.25 million. Legend Biotech had a negative net margin of 62.50% and a negative return on equity of 23.20%. The company's quarterly revenue was up 154.4% on a year-over-year basis. During the same period in the prior year, the business earned ($0.27) earnings per share. On average, research analysts anticipate that Legend Biotech will post -1.51 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Legend Biotech（纳斯达克：LEGN - 获取免费报告）于 8 月 9 日星期五发布了季度财报。公司报告的每股收益为（0.05）美元，超过了每股（0.54）美元的共识预期 0.49 美元。该季度公司营收为 1.865 亿美元，超过分析师预期的 1.2525 亿美元。Legend Biotech 的净利润率为-62.50%，净资产收益率为-23.20%。公司季度营收同比增长了 154.4%。在去年同期，公司每股收益为（0.27）美元。研究分析师平均预计，Legend Biotech 在本财年将实现-1.51 美元的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Legend Biotech</h2>
<div class="lb-trans"><h2>对 Legend Biotech 的对冲基金看法</h2>
</div><p>A number of hedge funds have recently made changes to their positions in LEGN. Blue Trust Inc. boosted its holdings in shares of Legend Biotech by 10,075.0% in the 2nd quarter. Blue Trust Inc. now owns 814 shares of the company's stock valued at $36,000 after purchasing an additional 806 shares during the last quarter. American International Group Inc. raised its stake in shares of Legend Biotech by 50.0% in the 1st quarter. American International Group Inc. now owns 900 shares of the company's stock valued at $50,000 after acquiring an additional 300 shares during the period. AM Squared Ltd purchased a new position in shares of Legend Biotech in the 2nd quarter valued at $71,000. California State Teachers Retirement System raised its stake in shares of Legend Biotech by 196.3% in the 1st quarter. California State Teachers Retirement System now owns 3,345 shares of the company's stock valued at $188,000 after acquiring an additional 2,216 shares during the period. Finally, BNP Paribas purchased a new position in shares of Legend Biotech in the 1st quarter valued at $199,000. Institutional investors and hedge funds own 70.89% of the company's stock.</p>
<div class="lb-trans"><p>最近，许多对冲基金对 LEGN 的持股进行了调整。Blue Trust Inc.在第二季度将其对 Legend Biotech 的持股增加了 10,075.0%。Blue Trust Inc.现在拥有公司股票 814 股，价值 36,000 美元，在上一季度购买了额外的 806 股。美国国际集团在第一季度将其对 Legend Biotech 的持股增加了 50.0%。美国国际集团现在拥有公司股票 900 股，价值 50,000 美元，在该期间额外增持了 300 股。AM Squared Ltd 在第二季度购入了一笔新的 Legend Biotech 持股，价值 71,000 美元。加州教师退休金基金在第一季度将其对 Legend Biotech 的持股增加了 196.3%。加州教师退休金基金现在拥有公司股票 3,345 股，价值 188,000 美元，在该期间额外增持了 2,216 股。最后，法国巴黎银行在第一季度购入了一笔新的 Legend Biotech 持股，价值 199,000 美元。机构投资者和对冲基金共拥有公司股份的 70.89%。</p>
</div><h2>Legend Biotech Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>Legend Biotech 公司简介（获取免费报告）</h2>
</div><p>Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).</p>
<div class="lb-trans"><p>Legend Biotech Corporation 是一家临床阶段生物制药公司，通过其子公司在美国、中国和国际市场从事新型细胞疗法在肿瘤学和其他适应症中的发现、开发、制造和商业化。其主要产品候选药物 LCAR-B38M 是一种用于多发性骨髓瘤（MM）治疗的嵌合抗原受体。</p>
</div><h2>See Also</h2>
<ul>
<li>Five stocks we like better than Legend Biotech</li>
<li>Stock Market Sectors: What Are They and How Many Are There?</li>
<li>Salesforce: Have You Seen The Latest Price Target Upgrade?</li>
<li>What are earnings reports?</li>
<li>Bright Minds Biosciences Stock Surges Almost 1,500%</li>
<li>REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today</li>
<li>Charles Schwab: Steady Performance, But Is There More to Come?</li>
</ul>
<div class="lb-trans"><h2>另请参阅</h2>
<ul>
<li>我们喜欢的五只股票胜过 Legend Biotech</li>
<li>股市行业：有多少种？</li>
<li>Salesforce：您看到最新的价格目标升级了吗？</li>
<li>什么是盈利报告？</li>
<li>Bright Minds Biosciences 股票涨幅近 1500%</li>
<li>房地产投资信托股票 - 添加到您的投资组合中的最佳房地产投资信托股票</li>
<li>查尔斯·施瓦布：稳定的表现，但还有更多要来吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEVHTg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=LEGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由 Narrative Science 技术和 MarketBeat 的财务数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ Are you prepared for November 5 (From Weiss Ratings)(Ad)</p>
<div class="lb-trans"><p>→ 您准备好迎接 11 月 5 日了吗（来自 Weiss Ratings）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05OTg4" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9988&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Legend Biotech right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资 1000 美元购买 Legend Biotech 股票？</h2>
</div><p>Before you consider Legend Biotech, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Legend Biotech 之前，您可能希望听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Legend Biotech wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街评级最高且表现最佳的研究分析师以及他们向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 Legend Biotech 并不在这份名单上。</p>
</div><p>While Legend Biotech currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管传奇生物目前在分析师中拥有&#34;买入&#34;评级，但顶级分析师认为以下五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

HC Wainwright 重申了传奇生物（NASDAQ: LEGN）的股票评级